Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:~  * major abscess requiring surgical incision and drainage;~ * infected burn (see exclusion criteria for important qualifications);~ * deep/extensive cellulitis;~ * infected ulcer (see exclusion criteria for important qualifications);~ * wound infections~* Patients must be expected to require at least 7 days of intravenous antibiotic treatment.~Exclusion Criteria:~* Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy~* Burns involving \> 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telavancin (Type: EXPERIMENTAL): None
- Vancomycin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).